VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ADXN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ADXNAddex Therapeutics Ltd
$3.18$2M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
ADXN logo

Addex Therapeutics Ltd

ADXN
NASDAQ · Neuroscience Biotech
$3.18
At close - Nov 18, 4:00 PM EST - USD
Market Cap$2M
P/E-0.6x
52W High$10.43
Volume57.63K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Persistent Milestone Dependence Threatens Corporate Liquidity Viability

Addex Therapeutics faces a precarious outlook as its reliance on sporadic milestone payments has failed to offset a persistent, high fixed-cost structure, leading to a significant erosion of shareholder equity from $12.7 million in 2024Q2 to $3.3 million by 2026Q1.

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

ADXN price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

1/12 Beats

EPS beat 1 of last 12 quarters

02

Valuation risk

-101% Peers

P/E is 101% below peer median

03

Market leadership

RS 17 · Lag

Laggard (Underperforming 83% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Dec 28

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
ADXN-60.69%
S&P 500 (^GSPC)+6.88%
1-Year Return
ADXN-64.51%
S&P 500 (^GSPC)+10.62%
3-Year Return
ADXN-49.52%
S&P 500 (^GSPC)+45.09%
5-Year Return
ADXN-97.88%
S&P 500 (^GSPC)+49.27%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y Low
-0.5x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-0.5x
0.8x
0th· Low
EV/EBITDA
N/A
N/A
N/A
Price/FCF
N/A
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
No DCF Model AvailableIntrinsic value modeling is not supported for this equity.

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$30K-92.6% YoY
Net income FY25
-$7M-195.4% YoY
Free cash flow FY25
-$2M+61.4% YoY
Operating margin FY25
-9390.8%-8708.9 pts YoY
ROIC (FY25)-44.3%
Avg ROIC 5Y-73.8%
ROE (TTM)-172.5%
Piotroski Score1 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate1/12 (11%)
Revenue Beat Rate1/12 (11%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Sep 28, 2026
-$1.49
vs —
$12,316
vs —
Q3 2026
Jun 25, 2026
-$1.53
vs —
$9,878
vs —
Q2 2026
Apr 30, 2026
-$1.94-36.0%
vs -$1.42
$313,000+32.3%
vs $236,616
Q4 2025
Dec 4, 2025
-$1.50
vs —
$37,364-84.2%
vs $236,616
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·Nov 11, 2026
Addex Spin-out Neurosterix Closes $105 Million Series B Financing

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 11, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, has closed a $105 million Series B financing from a syndicate of leading life science investors.

GlobeNewsWire·Oct 29, 2026
ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that 93,000,000 new registered shares at a nominal value of CHF 0.01 have been issued and fully subscribed by Addex Pharma S.A, its 100% wholly-owned subsidiary.

Defense World·Oct 19, 2026
Reviewing Addex Therapeutics (NASDAQ:ADXN) & Clene (NASDAQ:CLNN)

Clene (NASDAQ: CLNN - Get Free Report) and Addex Therapeutics (NASDAQ: ADXN - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation. Profitability This table compares Clene and Addex Therapeutics'

Defense World·Oct 10, 2026
Addex (NASDAQ: ADXN) spin-out Neurosterix clears Phase 1, plans next stage

What happened Addex Therapeutics Ltd. (NASDAQ: ADXN) said Neurosterix completed Phase 1 studies of NTX-253 and plans to move the drug into Phase 2. NTX-253 is a positive allosteric modulator of the muscarinic M4 receptor, and the program is being developed for schizophrenia. Addex said Neurosterix is its spin-out company and that Addex holds a

Filtered for Addex Therapeutics LtdMore Headlines
04

Compare before deciding

Benchmark ADXN against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Addex Therapeutics Ltd (ADXN)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ADXN logoADXNAddex Therapeutics LtdCurrent
$3.18$2.29M-0.57-92.58%-14429.21%-172.46%—
ACAD logoACADACADIA Pharmaceuticals Inc.
$17.83$3.05B8.6411.87%30.13%28.03%—
INVA logoINVAInnoviva, Inc.
$18.40$1.36B6.8618.52%43.79%15.84%—
PRAX logoPRAXPraxis Precision Medicines, Inc.
$305.19$8.51B-24.78-100%—-29.41%—
NBIX logoNBIXNeurocrine Biosciences, Inc.
$162.86$16.38B24.3921.45%18.98%19.74%—
FLNA logoFLNAFilana Therapeutics, Inc.
$0.55$26.33M-0.63——-63.91%—

Compare ADXN vs Peers

Addex Therapeutics Ltd (ADXN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ACAD

Most directly comparable listed peer for ADXN.

Scale Benchmark

vs LLY

Larger-name benchmark to compare ADXN against a more recognizable public peer.

Peer Set

Compare Top 5

vs ACAD, INVA, PRAX, NBIX

Get notified when ADXN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ADXN Frequently Asked Questions

Addex Therapeutics Ltd (ADXN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Addex Therapeutics Ltd's revenue?

Addex Therapeutics Ltd (ADXN) reported $0.0M in revenue over the trailing twelve months. Revenue was $0.0M in fiscal year 2025. That is 99% less than the $4.7M of fiscal year 2006.

How fast is Addex Therapeutics Ltd growing?

Addex Therapeutics Ltd (ADXN) revenue fell by 48.1% over the trailing twelve months, compared with the twelve months before.

Is ADXN profitable?

No. Addex Therapeutics Ltd (ADXN) reported a net loss of $6.9M over the trailing twelve months.

Dividend & Returns
What is ADXN's return on equity?

Addex Therapeutics Ltd (ADXN) had a return on equity (ROE) of -172.5% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Addex Therapeutics Ltd's free cash flow?

Addex Therapeutics Ltd (ADXN) had negative free cash flow of $2.4M over the trailing twelve months.

What if you invested $1,000 in ADXN back in 2006?

Total return calculator · dividends reinvested · 20+ years of data

See returns →